^
Association details:
| Biomarker: | SLC34A2-ROS1 fusion |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
Published date:
02/24/2021
Excerpt:
...gilteritinib also displayed potency against ROS1 fusion gene-expressing lung cancer cell lines (HCC78 cells harbor SLC34A2-ROS1 and JFCR-168 harbor CD74-ROS1…)
DOI:
10.1038/s41467-021-21396-w
